Second Sight Medical (NASDAQ: EYES) reported Q4 EPS of ($0.13), $0.01 better than the analyst estimate of ($0.14). Revenue for the quarter came in at $2.4 million versus the consensus estimate of $2.47 million.

2016 Objectives

• Secure coverage with additional MACs in the U.S. as well as other key markets globally;
• Work with CMS to establish Medicare reimbursement rates that cover the facility costs related to furnishing the Argus II to patients in 2017 and beyond;
• Expand our global footprint by continuing to grow the number of implanting centers and enter additional markets;
• Improve the Argus II technology, including significant R&D milestones for the next generation externals and advanced software;
• Complete enrollment of the Dry Age-Related Macular Degeneration feasibility clinical trial and finalize a go forward strategy; and
• Complete animal testing and file the IDE application with the FDA to test the Orion™ I Visual Cortical Prosthesis in humans.

For earnings history and earnings-related data on Second Sight Medical (EYES) click here.